JP2011523638A - うつ病に関するグルタミンバイオマーカー - Google Patents

うつ病に関するグルタミンバイオマーカー Download PDF

Info

Publication number
JP2011523638A
JP2011523638A JP2011508939A JP2011508939A JP2011523638A JP 2011523638 A JP2011523638 A JP 2011523638A JP 2011508939 A JP2011508939 A JP 2011508939A JP 2011508939 A JP2011508939 A JP 2011508939A JP 2011523638 A JP2011523638 A JP 2011523638A
Authority
JP
Japan
Prior art keywords
vivo imaging
polypeptide
polynucleotide
depression
compound
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2011508939A
Other languages
English (en)
Japanese (ja)
Other versions
JP2011523638A5 (https=
Inventor
ハンソン，ピーター
ヒスコック，ダンカン
モリス，クリス
トーマス，アラン
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
GE Healthcare Ltd
Original Assignee
GE Healthcare Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by GE Healthcare Ltd filed Critical GE Healthcare Ltd
Publication of JP2011523638A publication Critical patent/JP2011523638A/ja
Publication of JP2011523638A5 publication Critical patent/JP2011523638A5/ja
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/136—Screening for pharmacological compounds
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Analytical Chemistry (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Pathology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Pain & Pain Management (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Psychiatry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2011508939A 2008-05-15 2009-05-15 うつ病に関するグルタミンバイオマーカー Pending JP2011523638A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB0808833.8 2008-05-15
GBGB0808833.8A GB0808833D0 (en) 2008-05-15 2008-05-15 Biomarkers for depression
PCT/EP2009/055945 WO2009138501A1 (en) 2008-05-15 2009-05-15 Glutamine biomarkers for depression

Publications (2)

Publication Number Publication Date
JP2011523638A true JP2011523638A (ja) 2011-08-18
JP2011523638A5 JP2011523638A5 (https=) 2012-06-28

Family

ID=39571407

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2011508939A Pending JP2011523638A (ja) 2008-05-15 2009-05-15 うつ病に関するグルタミンバイオマーカー

Country Status (6)

Country Link
US (1) US20110064659A1 (https=)
EP (1) EP2281068A1 (https=)
JP (1) JP2011523638A (https=)
CN (1) CN102099490A (https=)
GB (1) GB0808833D0 (https=)
WO (1) WO2009138501A1 (https=)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2011523637A (ja) * 2008-05-15 2011-08-18 ジーイー・ヘルスケア・リミテッド うつ病に関するｇａｂａバイオマーカー
JP2011523636A (ja) * 2008-05-15 2011-08-18 ジーイー・ヘルスケア・リミテッド うつ病に関するバイオマーカー
WO2020202923A1 (ja) 2019-03-29 2020-10-08 日本たばこ産業株式会社 うつ病の評価方法及びうつ病の治療法の効果の評価方法、並びにうつ病若しくはうつ病の治療法の効果を評価するためのデータ取得方法

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2012223364A1 (en) * 2011-03-01 2013-09-19 Ge Healthcare Limited Radiolabelled Octreotate analogues as PET tracers
CN105759065B (zh) * 2016-02-26 2017-10-13 天津桑尼匹克生物科技有限公司 血液代谢标记物的用途及抑郁症检测试剂盒

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004047727A2 (en) * 2002-11-01 2004-06-10 The Board Of Trustees Of The Leland Stanford Junior University Compositions and methods for diagnosing and treating mood disorders
US20050209181A1 (en) * 2003-11-05 2005-09-22 Huda Akil Compositions and methods for diagnosing and treating mental disorders
US20070172830A1 (en) * 1998-05-12 2007-07-26 Human Genome Sciences, Inc. Antibodies to hhpen62 polypeptide
WO2008020435A2 (en) * 2006-08-15 2008-02-21 Quark Pharmaceuticals, Inc Compositions and methods for treatment of mood disorders
JP2011523637A (ja) * 2008-05-15 2011-08-18 ジーイー・ヘルスケア・リミテッド うつ病に関するｇａｂａバイオマーカー
JP2011523636A (ja) * 2008-05-15 2011-08-18 ジーイー・ヘルスケア・リミテッド うつ病に関するバイオマーカー

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2006513996A (ja) * 2002-10-24 2006-04-27 メルク　エンド　カムパニー　インコーポレーテッド 代謝調節型グルタミン酸受容体結合用トレーサーとしてのアルキン誘導体

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070172830A1 (en) * 1998-05-12 2007-07-26 Human Genome Sciences, Inc. Antibodies to hhpen62 polypeptide
WO2004047727A2 (en) * 2002-11-01 2004-06-10 The Board Of Trustees Of The Leland Stanford Junior University Compositions and methods for diagnosing and treating mood disorders
US20050209181A1 (en) * 2003-11-05 2005-09-22 Huda Akil Compositions and methods for diagnosing and treating mental disorders
WO2008020435A2 (en) * 2006-08-15 2008-02-21 Quark Pharmaceuticals, Inc Compositions and methods for treatment of mood disorders
JP2011523637A (ja) * 2008-05-15 2011-08-18 ジーイー・ヘルスケア・リミテッド うつ病に関するｇａｂａバイオマーカー
JP2011523636A (ja) * 2008-05-15 2011-08-18 ジーイー・ヘルスケア・リミテッド うつ病に関するバイオマーカー

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
JPN6013044979; Ｓｈｅｌｉｎｅ　ｅｔ　ａｌ．: ''Ｄｅｃｒｅａｓｅｄ　ｈｉｐｐｏｃａｍｐａｌ　５-ＨＴ（２Ａ）　ｒｅｃｅｐｔｏｒ　ｂｉｎｄｉｎｇ　ｉｎ　ｏｌｄｅｒ　ｄｅｐｒｅｓｓｅｄ　ｐａｔｉｅｎｔｓ　ｕｓｉｎｇ　［１８Ｆ］ａｌｔａｎｓｅｒｉｎ　ｐ' Ｎｅｕｒｏｐｓｙｃｈｏｐｈａｒｍａｃｏｌｏｇｙ ２９（１２）, 2004, ｐｐ．２２３５-４１ *

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2011523637A (ja) * 2008-05-15 2011-08-18 ジーイー・ヘルスケア・リミテッド うつ病に関するｇａｂａバイオマーカー
JP2011523636A (ja) * 2008-05-15 2011-08-18 ジーイー・ヘルスケア・リミテッド うつ病に関するバイオマーカー
WO2020202923A1 (ja) 2019-03-29 2020-10-08 日本たばこ産業株式会社 うつ病の評価方法及びうつ病の治療法の効果の評価方法、並びにうつ病若しくはうつ病の治療法の効果を評価するためのデータ取得方法

Also Published As

Publication number Publication date
WO2009138501A1 (en) 2009-11-19
CN102099490A (zh) 2011-06-15
EP2281068A1 (en) 2011-02-09
GB0808833D0 (en) 2008-06-18
US20110064659A1 (en) 2011-03-17

Similar Documents

Publication Publication Date Title
Farrell et al. DNA methylation differences at the glucocorticoid receptor gene in depression are related to functional alterations in hypothalamic–pituitary–adrenal axis activity and to early life emotional abuse
Laruelle Imaging dopamine transmission in schizophrenia: a review and meta-analysis
JP2011523636A (ja) うつ病に関するバイオマーカー
Malison et al. Reduced brain serotonin transporter availability in major depression as measured by [123I]-2β-carbomethoxy-3β-(4-iodophenyl) tropane and single photon emission computed tomography
Arcos-Burgos et al. A common variant of the latrophilin 3 gene, LPHN3, confers susceptibility to ADHD and predicts effectiveness of stimulant medication
Nestadt et al. Genetics of OCD
Patel et al. Positron emission tomography in schizophrenia: a new perspective
CN106434870A (zh) ncRNA及其用途
JP2011523637A (ja) うつ病に関するｇａｂａバイオマーカー
Hernandez et al. Abnormal expression of serotonin transporter mRNA in the frontal and temporal cortex of schizophrenics
Hart et al. Genetic factors modulating the response to stimulant drugs in humans
CN101490553A (zh) 用parp抑制剂治疗疾病的方法
JP2011523638A (ja) うつ病に関するグルタミンバイオマーカー
Smith et al. Translational research in late-life mood disorders: implications for future intervention and prevention research
Ibrahim et al. Early Onset Parkinsonism: Differential diagnosis and what not to miss
Alkelai et al. Identification of new schizophrenia susceptibility loci in an ethnically homogeneous, family‐based, Arab‐Israeli sample
CN110042153A (zh) 一种smn1基因突变的检测方法及其引物组
Brust et al. Neuroimaging of the serotonin transporter: possibilities and pitfalls
Kong et al. Progress and Implications from Genetic Studies of Bipolar Disorder
WO2006117945A1 (en) Method for detecting lipid metabolism disorder, and diagnostic agent for use therein
JP6807094B2 (ja) クロザピン又はその誘導体の血中薬剤濃度上昇リスク判定方法及び薬剤投与量判定方法
Turner et al. Amyotrophic Lateral Sclerosis
Dobrin Genomics of schizophrenia
Fonseca Casals Pharmacogenomic study of oppioid addicts in methadone treatment
Donohoe et al. Cognitive intermediate phenotypes in schizophrenia genetics

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20120510

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20120510

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20130910

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20140304